Olema Pharmaceuticals, Inc. announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company's complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatment of metastatic breast cancer, at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023. Details of the ESMO Congress 2023 mini oral session presentation are: Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) inhibitor (CERAN) and select ER degrader (SER D). The company will host a webcast and conference call for analysts and investors to review data presented at the ESMO Congress 2023 as well as other ongoing studies on October 23, 2023, at 8:00 a.m. ET (2:00 p.m. CEST).